It seems FDA isn't as comfortable as some thought about letting Sanofi-Aventis ' much-vaunted obesity candidate rimonabant (Acomplia) onto the market. The agency in February issued an approvable letter for the first-in-class cannabinoid-1 receptor antagonist in weight management—meaning further information is required--and a not approvable in smoking cessation, which is basically a "No."
The news hit the headlines, nudging Sanofi-Aventis' share price down by a few percentage points. Acomplia is one of the most widely anticipated new drugs, with analyst peak sales forecasts...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?